Myriad Genetics (NASDAQ:MYGN) vs. ADMA Biologics (NASDAQ:ADMA) Financial Review

ADMA Biologics (NASDAQ:ADMA) and Myriad Genetics (NASDAQ:MYGN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Analyst Recommendations

This is a summary of recent recommendations for ADMA Biologics and Myriad Genetics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADMA Biologics	0	3	3	0	2.50
Myriad Genetics	3	4	1	0	1.75

ADMA Biologics presently has a consensus price target of $18.67, indicating a potential upside of 80.18%. Myriad Genetics has a consensus price target of $3.93, indicating a potential downside of 8.74%. Given ADMA Biologics’ stronger consensus rating and higher probable upside, equities analysts plainly believe ADMA Biologics is more favorable than Myriad Genetics.

Insider and Institutional Ownership

75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 3.9% of ADMA Biologics shares are held by insiders. Comparatively, 1.9% of Myriad Genetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares ADMA Biologics and Myriad Genetics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADMA Biologics	$510.17 million	4.55	$146.93 million	$0.70	14.80
Myriad Genetics	$824.50 million	0.50	-$365.90 million	($1.19)	-3.62

ADMA Biologics has higher earnings, but lower revenue than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

ADMA Biologics has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500.

Profitability

This table compares ADMA Biologics and Myriad Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ADMA Biologics	32.98%	40.17%	26.97%
Myriad Genetics	-13.96%	-16.09%	-8.10%

Summary

ADMA Biologics beats Myriad Genetics on 11 of the 14 factors compared between the two stocks.

About ADMA Biologics

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

About Myriad Genetics

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.